<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442020000300082</article-id>
<article-id pub-id-type="doi">10.24875/rmn.20000089</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Preventive treatment in migraine. Used drugs and related variables. Results of the European work and migraine survey]]></article-title>
<article-title xml:lang="es"><![CDATA[Tratamiento preventivo en migraña. Fármacos usados y variables relacionadas. Resultados de la encuesta europea sobre trabajo y migraña]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vicente-Herrero]]></surname>
<given-names><![CDATA[María Teófila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Iñiguez de la Torre]]></surname>
<given-names><![CDATA[María Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruíz-de la Torre]]></surname>
<given-names><![CDATA[Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reinoso-Barbero]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Spanish Association of Specialists in Occupational Medicine  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,European Migraine and Headache Alliance  ]]></institution>
<addr-line><![CDATA[Brussels ]]></addr-line>
<country>Belgium</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Spanish Association of Specialists in Occupational Medicine  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<fpage>82</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442020000300082&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442020000300082&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442020000300082&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Migraine is a chronic debilitating and costly illness, the etiology of which is not yet fully known. Treatment is based on the control of acute attacks and the prophylactic management of chronic forms.  Objective: The objective of this study is to find out the migraine preventive treatments which are used by patients in different countries in Europe, as well as observing the differences according to their social and demographic conditions.  Methods: A cross-sectional observational study performed by means of an anonymous web-based survey of 3342 patients from Spain, Italy, France, Portugal, Ireland, United Kingdom, Germany, and other European Union (EU) countries.  Study variables: Age, gender, country, type of town/city, level of studies completed, and rural or urban area have been dismissed. The different uses of preventive treatments are defined as: i always take preventive treatments, I take seasonal preventive treatments, I do not take preventive treatments, I do not know what a preventive treatment is.  Results: The regular use of preventive treatments increases with age, their use is greater in patients over the age of 40 years (p &lt; 0.0001), and they are most commonly used in Spain, Germany, United Kingdom, Italy, and in the rest of the countries in the EU (p &lt; 0.0001). Out of all of the countries included in this survey, Spain has the highest use of seasonal preventive medication (p &lt; 0.0001). The lowest use of preventive treatments is in patients under the age of 40 years (p = 0.002) and in female patients (p = 0.028). The highest percentages of patients who do not use preventive treatments (p &lt; 0.0001) are from Spain, Germany, and the rest of the countries in the EU. Young patients under the age of 40 years (p &lt; 0.0001), patients in Spain, Germany, and the rest of the countries in the EU that were not included in the initial design (p &lt; 0.0001) have the greatest lack of knowledge with regard to preventive treatments.  Conclusions: The use of preventive pharmacological therapies in migraine remains low despite the fact that these therapies are scientifically backed. It is important to further develop the training of physicians and reinforce patient information, assessing patient preferences to improve their adherence to treatment.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La migraña es un trastorno crónico incapacitante y costoso, cuya etiología aún no se conoce completamente; el tratamiento se basa en el control de los ataques agudos y el manejo profiláctico de las formas crónicas.  Objetivo: El objetivo de este trabajo es descubrir el uso de tratamientos preventivos en pacientes con migraña de países europeos y las diferencias observadas según sus condiciones sociales y demográficas.  Método: Estudio observacional transversal mediante encuesta web anónima a 3342 pacientes de España, Italia, Francia, Portugal, Irlanda, Reino Unido, Alemania y otros países de la Unión Europea (UE). Variables de estudio: edad, sexo, país, tipo de ubicación, nivel de estudios y área rural o urbana. Las opciones de uso de los tratamientos preventivos recopilados son: tratamientos preventivos siempre, tratamientos preventivos en temporadas, «no tomo tratamiento preventivo» y «no sé qué es un tratamiento preventivo».  Resultados: El uso de tratamientos preventivos es superior en los mayores de 40 años (p &lt; 0.0001), con la mayor utilización en España, Alemania, Reino Unido, Italia y el resto de los países de la UE no incluidos en el diseño inicial (p &lt; 0.0001). España es el país con mayor uso de preventivos en temporadas (estacional) (p &lt; 0.0001). El uso más bajo de tratamientos preventivos ocurre en personas menores de 40 años (p = 0.002) y en mujeres (p = 0.028). España, Alemania y el resto de los países de la UE tienen el mayor porcentaje de pacientes sin tratamiento preventivo (p &lt; 0.0001). La mayor falta de conocimiento sobre los preventivos ocurre en pacientes con menos de 40 años de edad (p &lt; 0.0001), en España, Alemania y el resto de los países de la UE no incluidos en el diseño inicial (p &lt; 0.0001).  Conclusiones: El uso de terapias farmacológicas preventivas en la migraña sigue siendo bajo a pesar de contar con respaldo científico. Es importante reforzar la capacitación del médico y la información al paciente, evaluando las preferencias del paciente para mejorar su adherencia al tratamiento.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Migraine]]></kwd>
<kwd lng="en"><![CDATA[Preventive treatment]]></kwd>
<kwd lng="en"><![CDATA[Public health]]></kwd>
<kwd lng="es"><![CDATA[Migraña]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento preventivo]]></kwd>
<kwd lng="es"><![CDATA[Salud pública]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harmon]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of migraines and migraine variants]]></article-title>
<source><![CDATA[Prim Care]]></source>
<year>2015</year>
<volume>42</volume>
<page-range>233-41</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pomes]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Guglielmetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bertamino]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Simmaco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martelletti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimising migraine treatment:from drug-drug interactions to personalized medicine]]></article-title>
<source><![CDATA[J Headache Pain]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Do]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ashina]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic novelties in migraine:new drugs, new hope?]]></article-title>
<source><![CDATA[J Headache Pain]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>37</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Iyer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physician and patient preferences for dosing options in migraine prevention]]></article-title>
<source><![CDATA[J Headache Pain]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>50</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dodick]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Loder]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Manack Adams]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Fanning]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing barriers to chronic migraine consultation, diagnosis, and treatment:results from the chronic migraine epidemiology and outcomes (CaMEO) study]]></article-title>
<source><![CDATA[Headache]]></source>
<year>2016</year>
<volume>56</volume>
<page-range>821-34</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grazzi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bussone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gingkolide B as migraine preventive treatment in young age:results at 1-year follow-up]]></article-title>
<source><![CDATA[Neurol Sci]]></source>
<year>2011</year>
<volume>32</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S197-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedraza Hueso]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz Piñero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Velasco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Juanatey García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero Peral]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Headache in young patients:clinical characteristics of a series of 651 cases]]></article-title>
<source><![CDATA[Neurologia]]></source>
<year>2019</year>
<volume>34</volume>
<page-range>22-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Usai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grazzi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Andrasik]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bussone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An innovative approach for migraine prevention in young age:a preliminary study]]></article-title>
<source><![CDATA[Neurol Sci]]></source>
<year>2010</year>
<volume>31</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S181-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipton]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Munjal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Fanning]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Migraine in America symptoms and treatment (MAST) study:baseline study methods, treatment patterns, and gender differences]]></article-title>
<source><![CDATA[Headache]]></source>
<year>2018</year>
<volume>58</volume>
<page-range>1408-26</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Azorin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santos-Lasaosa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gago-Veiga]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Guerrero-Peral]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real world preventative drug management of migraine among Spanish neurologists]]></article-title>
<source><![CDATA[J Headache Pain]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martelletti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schwedt]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lanteri-Minet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carboni]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Diener]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[My migraine voice survey:a global study of disease burden among individuals with migraine for whom preventive treatments have failed]]></article-title>
<source><![CDATA[J Headache Pain]]></source>
<year>2018</year>
<volume>19</volume>
<page-range>115</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woldeamanuel]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Migraine affects 1 in 10 people worldwide featuring recent rise:a systematic review and meta-analysis of community-based studies involving 6 million participants]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2017</year>
<volume>372</volume>
<page-range>307-15</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pringsheim]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Davenport]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mackie]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Worthington]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Aubé]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Christie]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canadian headache society guideline for migraine prophylaxis]]></article-title>
<source><![CDATA[Can J Neurol Sci]]></source>
<year>2012</year>
<volume>39</volume>
<page-range>S1-59</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silberstein]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preventive migraine treatment]]></article-title>
<source><![CDATA[Continuum (Minneap Minn)]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>973-89</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matza]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Deger]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Vo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maniyar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Goadsby]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2019</year>
<volume>28</volume>
<page-range>2359-72</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seng]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Rains]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholson]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Lipton]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving medication adherence in migraine treatment]]></article-title>
<source><![CDATA[Curr Pain Headache Rep]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>24</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woolley]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bonafede]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Maiese]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Lenz]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States]]></article-title>
<source><![CDATA[Headache]]></source>
<year>2017</year>
<volume>57</volume>
<page-range>1399-408</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hepp]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Dodick]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Varon]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Chia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Matthew]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gillard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine:a retrospective claims analysis]]></article-title>
<source><![CDATA[Cephalalgia]]></source>
<year>2017</year>
<volume>37</volume>
<page-range>470-85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peres]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Silberstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Corchs]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vieira]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients'preference for migraine preventive therapy]]></article-title>
<source><![CDATA[Headache]]></source>
<year>2007</year>
<volume>47</volume>
<page-range>540-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dekker]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Knuistingh Neven]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andriesse]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kernick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic treatment of migraine;the patient's view, a qualitative study]]></article-title>
<source><![CDATA[BMC Fam Pract]]></source>
<year>2012</year>
<volume>13</volume>
<page-range>13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
